CASI
CASI Pharmaceuticals·NASDAQ
--
--(--)
--
--(--)
CASI Filings
Filing Date
Form Description
Form Type
2026-01-29
Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
2026-01-29 ·
Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
2026-01-28
Form D - Notice of Exempt Offering of Securities
2026-01-28 ·
Form D - Notice of Exempt Offering of Securities
2026-01-28
Form D - Notice of Exempt Offering of Securities
2026-01-28 ·
Form D - Notice of Exempt Offering of Securities
2026-01-22
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Key Events
2026-01-22 · Key Events
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2026-01-20
Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
2026-01-20 ·
Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
2026-01-20
Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
2026-01-20 ·
Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
2026-01-13
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Key Events
2026-01-13 · Key Events
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2026-01-09
Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
2026-01-09 ·
Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
2025-12-31
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Key Events
2025-12-31 · Key Events
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2025-12-23
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Key Events
2025-12-23 · Key Events
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
